A rare case of a pancreatic mass due to accessory spleen; when EUS-FNA is not enough.

Auteurs : Toussaint E, Flamen P, Demetter P, Matos C, Van Gossum M, Delhaye M, Closset J, Loi P, Deviere J, Arvanitakis M
Jaar : 2011
Journal : Endoscopy
Volume : 43 Suppl 2 UCTN(null)
Pagina's : E221-2

Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.

Auteurs : Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P, Hendlisz A, Flamen P, Buvat I
Jaar : 2011
Journal : J. Nucl. Med.
Volume : 52(3)
Pagina's : 354-61

HER2-positive circulating tumor cells in breast cancer.

Auteurs : Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : PLoS One
Volume : 6(1)
Pagina's : e15624

Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).

Auteurs : Altintas S, Toussaint J, Durbecq V, Lambein K, Huizing MT, Larsimont D, Van Marck E, Vermorken JB, Tjalma WA, Sotiriou C
Jaar : 2011
Journal : Breast J
Volume : 17(4)
Pagina's : 343-51

Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.

Auteurs : Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart-Gebhart M
Jaar : 2011
Journal : PLoS One
Volume : 6(6)
Pagina's : e20980

Gene profiling assay and application: the predictive role in primary therapy.

Auteurs : Fumagalli D, Desmedt C, Ignatiadis M, Loi S, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pagina's : 124-7

Largest ever DNA methylation dataset for breast cancer completed.

Auteurs : Dedeurwaerder S, Desmedt C, Calonne E
Jaar : 2011
Journal : Expert Rev. Mol. Diagn.
Volume : 11(5)
Pagina's : 470

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.

Auteurs : Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Brunak S, Richardson AL, Szallasi Z
Jaar : 2011
Journal : BMC Bioinformatics
Volume : 12(null)
Pagina's : 310

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Auteurs : Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H
Jaar : 2011
Journal : Lancet Oncol
Volume : 12(12)
Pagina's : 1134-42

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Auteurs : Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart-Gebhart M, Sotiriou C
Jaar : 2011
Journal : Endocr Relat Cancer
Volume : 18(6)
Pagina's : 721-30

Multiple-input multiple-output causal strategies for gene selection.

Auteurs : Bontempi G, Haibe-Kains B, Desmedt C, Sotiriou C, Quackenbush J
Jaar : 2011
Journal : BMC Bioinformatics
Volume : 12(1)
Pagina's : 458

DNA methylation profiling reveals a predominant immune component in breast cancers.

Auteurs : Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart-Gebhart M, Sotiriou C, Fuks F
Jaar : 2011
Journal : EMBO Mol Med
Volume : 3(12)
Pagina's : 726-41

Neoadjuvant chemotherapy and targeted therapies: a promising strategy.

Auteurs : Metzger-Filho O, de Azambuja E
Jaar : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pagina's : 116-9

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Auteurs : Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G
Jaar : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pagina's : 147-51

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

Auteurs : Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM
Jaar : 2011
Journal : Eur. J. Heart Fail.
Volume : 13(1)
Pagina's : 1-10

Motherhood after breast cancer: searching for la dolce vita.

Auteurs : Azim HA, Peccatori FA, de Azambuja E, Piccart-Gebhart M
Jaar : 2011
Journal : Expert Rev Anticancer Ther
Volume : 11(2)
Pagina's : 287-98

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Auteurs : Bozovic-Spasojevic I, Azim HA, Paesmans M, Suter T, Piccart-Gebhart M, de Azambuja E
Jaar : 2011
Journal : Lancet Oncol
Volume : 12(3)
Pagina's : 209-11

Multifactorial approach to predicting resistance to anthracyclines.

Auteurs : Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L
Jaar : 2011
Journal : J. Clin. Oncol.
Volume : 29(12)
Pagina's : 1578-86

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

Auteurs : Azim HA, de Azambuja E, Colozza M, Bines J, Piccart-Gebhart M
Jaar : 2011
Journal : Ann Oncol
Volume : 22(9)
Pagina's : 1939-47

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Auteurs : Saini KS, Azim HA, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Jaar : 2011
Journal : Breast
Volume : 20 Suppl 3
Pagina's : S20-7